NCT03002090

Brief Summary

Iron deficiency is known to negatively impact physical performance, attention, and time spent doing physical activity. As a result, an iron deficient person must expend more energy to complete the same amount of work as someone who is healthy. Another interesting relationship has been observed between exercise training and iron status in that women who participate in exercise training often have higher rates of iron deficiency than sedentary women. ID is commonly treated using daily iron supplementation. However, it is currently unknown whether participating in regular exercise somehow impacts the effectiveness of iron supplementation. Iron deficient women who participate in exercise programs may potentially benefit less from iron supplementation than those who do not. Another common treatment for the symptoms of iron deficiency is the traditional Chinese herbal treatment, Ba-Zhen-Ke-Li (BZKL). While studies have shown that BZKL impacts expression of some iron-related proteins and increases endurance performance in rats, no studies have examined the efficacy of BZKL in improving iron markers or physical performance in humans. This study will compare the efficacy of BZKL in improving iron status and physical performance with that of ferrous sulfate supplementation. The Cornell research team will achieve these objectives in collaboration with colleagues at Kunming Medical University (KMU) in Kunming, China. A double-blind, randomized, placebo controlled study will be conducted by a Cornell graduate student at KMU. The subjects will be healthy women, age 18-26 years, attending KMU. Blood samples will be collected and analyzed for measures of iron). Subjects will be randomly assigned to receive 50 mg of ferrous sulfate (10 mg of elemental iron), 6mg of BZKL, or an identical placebo pill twice daily for 8 weeks. Subjects will be further randomly sub-divided to receive aerobic exercise training or no training during the 8-week supplementation period. At weeks 4 and 8, subjects will perform the same series of tests as was performed at baseline. The investigators hypothesize that: 1. the women who train and received iron will have smaller improvements in iron status than those who do not train 2. The women who receive iron and train will have greater improvements in physical performance than those who train and do not receive iron, and 3. The women who receive BZKL will improve their iron status or physical performance more than those who receive placebo.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
109

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2014

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2014

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

December 14, 2016

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 23, 2016

Completed
Last Updated

December 23, 2016

Status Verified

December 1, 2016

Enrollment Period

10 months

First QC Date

December 14, 2016

Last Update Submit

December 20, 2016

Conditions

Keywords

iron deficiencyanemiaexercise trainingaerobicperformanceChinese medicineBaZhen KeLi

Outcome Measures

Primary Outcomes (5)

  • Concentration of serum ferritin in µg/L

    Changes from week 0 to weeks 4 and 8 measured both within and between groups.

    Change in concentration of the 5 biomarkers from weeks 0 to 8. Change in concentration of the 5 biomarkers from weeks 0 to 4.

  • Concentration of soluble transferrin receptor in mg/L

    Changes from week 0 to weeks 4 and 8 measured both within and between groups.

    Change in concentration of the 5 biomarkers from weeks 0 to 8. Change in concentration of the 5 biomarkers from weeks 0 to 4.

  • Concentration of hemoglobin g/L

    Changes from week 0 to weeks 4 and 8 measured both within and between groups.

    Change in concentration of the 5 biomarkers from weeks 0 to 8. Change in concentration of the 5 biomarkers from weeks 0 to 4.

  • Concentration of alpha-1-acid glycoprotein in g/L

    Changes from week 0 to weeks 4 and 8 measured both within and between groups.

    Change in concentration of the 5 biomarkers from weeks 0 to 8. Change in concentration of the 5 biomarkers from weeks 0 to 4.

  • Concentration of C-reactive protein in mg/L

    Changes from week 0 to weeks 4 and 8 measured both within and between groups.

    Change in concentration of the 5 biomarkers from weeks 0 to 8. Change in concentration of the 5 biomarkers from weeks 0 to 4.

Secondary Outcomes (2)

  • Human performance as assessed by maximal capacity for oxygen uptake (mL/min/kg body weight)

    Change from weeks 0 to 8. Change from weeks 0 to 4.

  • Human performance as assessed by energetic efficiency (in %)

    Change from weeks 0 to 8. Change from weeks 0 to 4.

Study Arms (6)

Iron trained

EXPERIMENTAL
Dietary Supplement: Iron trained

Iron Untrained

EXPERIMENTAL
Dietary Supplement: Iron Untrained

BZKL Trained

EXPERIMENTAL
Dietary Supplement: BZKL Trained

BZKL Untrained

EXPERIMENTAL
Dietary Supplement: BZKL Untrained

Placebo Trained

EXPERIMENTAL
Dietary Supplement: Placebo Trained

Placebo Untrained

PLACEBO COMPARATOR
Dietary Supplement: Placebo Untrained

Interventions

Iron trainedDIETARY_SUPPLEMENT

1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability. 2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.

Iron trained
Iron UntrainedDIETARY_SUPPLEMENT

1\. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.

Iron Untrained
BZKL TrainedDIETARY_SUPPLEMENT

1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron. 2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.

BZKL Trained
BZKL UntrainedDIETARY_SUPPLEMENT

1\. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.

BZKL Untrained
Placebo TrainedDIETARY_SUPPLEMENT

1\. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.

Placebo Trained
Placebo UntrainedDIETARY_SUPPLEMENT

No intervention

Placebo Untrained

Eligibility Criteria

Age18 Years - 26 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age 18-26
  • Must be able to complete exercise on a stationary bicycle
  • Clinical diagnosis of iron depletion without severe anemia (sFer\< 25µg/L, Hb\>110g/L)
  • Willing to comply with the 8-week supplementation and if assigned, training program

You may not qualify if:

  • age less than 18
  • severe anemia (Hb\<90g/L in blood analyses)
  • current pregnancy or pregnancy within the previous year
  • recent infectious illness or fever
  • current inflammation or chronic inflammatory diseases (AGP \> 1.0 g/L in blood analyses)
  • hemolytic anemia
  • chronic respiratory disease
  • musculoskeletal problems
  • history of eating disorders
  • smoking, BMI \< 18 or \>24 kg/m2
  • consumption of medications that may affect dietary iron intake or absorption or that have anticoagulant properties
  • participation in varsity sports team

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kunming Medical University, Department of Nursing,

Longcheng, Yunnan, China

Location

Related Publications (2)

  • Pompano LM, Haas JD. Increasing Iron Status through Dietary Supplementation in Iron-Depleted, Sedentary Women Increases Endurance Performance at Both Near-Maximal and Submaximal Exercise Intensities. J Nutr. 2019 Feb 1;149(2):231-239. doi: 10.1093/jn/nxy271.

  • Pompano LM, Haas JD. Efficacy of iron supplementation may be misinterpreted using conventional measures of iron status in iron-depleted, nonanemic women undergoing aerobic exercise training. Am J Clin Nutr. 2017 Dec;106(6):1529-1538. doi: 10.3945/ajcn.117.152777. Epub 2017 Nov 1.

MeSH Terms

Conditions

Iron DeficienciesAnemia

Condition Hierarchy (Ancestors)

Iron Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Jere Haas, PhD

    Cornell University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 14, 2016

First Posted

December 23, 2016

Study Start

August 1, 2014

Primary Completion

June 1, 2015

Study Completion

June 1, 2015

Last Updated

December 23, 2016

Record last verified: 2016-12

Data Sharing

IPD Sharing
Will not share

Locations